Aimed Bio EV/FCF

Que fait Aimed Bio ? Aimed Bio Inc is a company based in Seoul, South Korea, with its headquarters located in the city. The company is set to go public on December 4, 2025, as indicated by its IPO date. Aimed Bio Inc is engaged in the development and research of anticancer drugs, focusing on antibody-based therapeutics, antibody-drug conjugates (ADCs), and bispecific antibodies. The company utilizes a platform it refers to as P-ADC, which is described as a precision-driven approach aimed at achieving definitive cures, distinguishing its development process from traditional methods. The company's website is https://www.aimedbio.com/, and it operates within the pharmaceutical sector, though specific industry details are not provided. Aimed Bio Inc is a Korea-based entity, and its operational focus is on advancing drug development through innovative therapeutic strategies. The company's activities are centered on creating new treatments for cancer, leveraging advanced biotechnology to design targeted therapies. No additional details regarding its founding year, key personnel, acquisitions, or specific product names are available in the provided information. The company's market presence is anticipated to grow following its IPO, though current market data is not specified. Aimed Bio est l'une des entreprises les plus populaires sur Eulerpool.